title: The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism.
abstract: The estradiol metabolism may be of clinical relevance in the pathophysiology of various diseases; the increase in D-ring metabolites over A-ring metabolites in breast cancer patients is of special interest. Since estrogen therapy has been blamed for increasing the risk of breast cancer, the effects of hormonal replacement therapy (HRT) and oral contraception were investigated on the ratio of the main D-ring metabolite, 16alpha-hydroxyestrone (16-OHE1), to the main A-ring metabolite, 2-hydroxyestrone (2-OHE1). In our study, hormone replacement therapy (HRT) in postmenopausal women consisted of administration of estradiol valerate either with or without addition of the progestin dienogest. In the second part of the study, women of reproductive age received ethinylestradiol plus dienogest or ethinylestradiol plus norethisterone acetate as oral contraceptives (OC). 2-OHE1 and 16-OHE1 were measured by enzyme immunoassay in 8 h night-urine collected before and after 3 months of hormone administration. With HRT, that is, estradiol valerate or estradiol valerate plus dienogest, the ratios before treatment were 0.47 and 0.60; after 3 months, they were 0.54 and 0.52, respectively. There were no significant differences. With oral contraception, that is, ethinylestradiol plus dienogest or norethisterone acetate, the ratios before administration were 0.62 and 0.68, vs. 0.31 and 0.54 after 3 months, respectively. The ratio after ethinylestradiol and dienogest was significantly lower after treatment. HRT and OC in the estrogen-progestin combinations tested did not impose any negative effects on estradiol metabolism--they did not elicit a higher D-ring metabolism, which is considered to increase breast cancer risk.
authors.affiliation: Section of Endocrinology and Menopause, Department of Obstetrics and Gynecology, University of Tübingen, Schleichstrasse 4, 72076 Tübingen, Germany.
authors.forename: A O
authors.initials: AO
authors.lastname: Mueck
authors.forename: H
authors.initials: H
authors.lastname: Seeger
authors.forename: T
authors.initials: T
authors.lastname: Gräser
authors.forename: M
authors.initials: M
authors.lastname: Oettel
authors.forename: T H
authors.initials: TH
authors.lastname: Lippert
mesh_terms: D000328:Adult; D003276:Contraceptives, Oral / Q000494:pharmacology*; D004958:Estradiol / Q000008:administration & dosage / Q000378:metabolism*; D015914:Estrogen Replacement Therapy; D002393:Estrogens, Catechol / Q000652:urine; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006894:Hydroxyestrones / Q000652:urine; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D017698:Postmenopause
chemical_list: D003276:Contraceptives, Oral; D002393:Estrogens, Catechol; D006894:Hydroxyestrones; C026702:16-hydroxyestrone; D004997:Ethinyl Estradiol; C023635:dienogest; D004958:Estradiol; D009277:Nandrolone; D000077563:Norethindrone Acetate; D009640:Norethindrone; C024980:2-hydroxyestrone